NovoCure Ltd. ((NVCR)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NovoCure Ltd. is conducting a study titled ‘Tumor Treating Fields General Routine Clinical Care in Newly Diagnosed Glioblastoma Patients: a French Prospective Non-Interventional Study – TIGER France.’ The study aims to confirm the survival benefits of the Optune Gio® device in terms of overall survival (OS) and progression-free survival (PFS) for patients with newly diagnosed glioblastoma (GBM) in France. It also seeks to evaluate the device’s impact on quality of life (QoL) in a real-world setting.
The intervention being tested is the Optune Gio®, a device designed to improve survival rates and quality of life for GBM patients. It is used alongside maintenance temozolomide (TMZ) after initial treatments like surgery, radiotherapy, and concomitant TMZ.
This observational study is prospective in nature, meaning it follows participants over time to observe outcomes. It is non-interventional, focusing on real-world data collection without altering standard treatment protocols.
The study began on September 18, 2024, and is currently recruiting participants. The last update was submitted on April 4, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment efforts.
The study’s findings could significantly impact NovoCure’s stock performance by validating the Optune Gio®’s effectiveness, potentially boosting investor confidence. In the competitive landscape of cancer treatment, positive results could position NovoCure favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.